Thromboembolism - Pipeline Review, H2 2014

Publisher Name :
Date: 31-Dec-2014
No. of pages: 92
Inquire Before Buying

Global Markets Direct's, ‘Thromboembolism Pipeline Review, H2 2014', provides an overview of the Thromboembolism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Thromboembolism

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Thromboembolism and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products


Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Thromboembolism

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Thromboembolism - Pipeline Review, H2 2014

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thromboembolism Overview 8
Therapeutics Development 9
Pipeline Products for Thromboembolism - Overview 9
Pipeline Products for Thromboembolism - Comparative Analysis 10
Thromboembolism - Therapeutics under Development by Companies 11
Thromboembolism - Therapeutics under Investigation by Universities/Institutes 13
Thromboembolism - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Thromboembolism - Products under Development by Companies 17
Thromboembolism - Products under Investigation by Universities/Institutes 18
Thromboembolism - Companies Involved in Therapeutics Development 19
AstraZeneca PLC 19
Bayer AG 20
Cereno Scientific AB 21
CSL Limited 22
Daiichi Sankyo Company, Limited 23
Gamma Therapeutics, Inc. 24
Green Cross Corporation 25
Isis Pharmaceuticals, Inc. 26
Portola Pharmaceuticals, Inc. 27
Regado Biosciences, Inc. 28
Sanofi 29
Thromboembolism - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
AZ-12971554 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
betrixaban - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
C-3 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CSL-3F7 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
edoxaban tosylate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Gammarin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
GCC-2107 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ISIS-FXIRx - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Lysimab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Protein for Thromboembolism and Blood Coagulation - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
REG-2 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
rivaroxaban - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
semuloparin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit HDAC for Thromboembolism - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
TAP-ANV - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
YG-001 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Thromboembolism - Recent Pipeline Updates 63
Thromboembolism - Dormant Projects 80
Thromboembolism - Discontinued Products 81
Thromboembolism - Product Development Milestones 82
Featured News & Press Releases 82
Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 82
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 82
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 84
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 84
Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan 85
Aug 30, 2014: Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) 85
Jun 23, 2014: Regado Biosciences REG2 Demonstrates Dose and Concentration Dependent Suppression of Thrombin Generation 86
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 87
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 88
May 12, 2014: Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO 89
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Tables

Number of Products under Development for Thromboembolism, H2 2014 9
Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Thromboembolism - Pipeline by AstraZeneca PLC, H2 2014 19
Thromboembolism - Pipeline by Bayer AG, H2 2014 20
Thromboembolism - Pipeline by Cereno Scientific AB, H2 2014 21
Thromboembolism - Pipeline by CSL Limited, H2 2014 22
Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 23
Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H2 2014 24
Thromboembolism - Pipeline by Green Cross Corporation, H2 2014 25
Thromboembolism - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 26
Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 27
Thromboembolism - Pipeline by Regado Biosciences, Inc., H2 2014 28
Thromboembolism - Pipeline by Sanofi, H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Thromboembolism Therapeutics - Recent Pipeline Updates, H2 2014 63
Thromboembolism - Dormant Projects, H2 2014 80
Thromboembolism - Discontinued Products, H2 2014 81

List of Figures

Number of Products under Development for Thromboembolism, H2 2014 9
Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Products, H2 2014 16
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Top 10 Targets, H2 2014 31
Number of Products by Stage and Top 10 Targets, H2 2014 31
Number of Products by Top 10 Mechanism of Actions, H2 2014 33
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 33
Number of Products by Top 10 Routes of Administration, H2 2014 35
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 35
Number of Products by Top 10 Molecule Types, H2 2014 37
Number of Products by Stage and Top 10 Molecule Types, H2 2014 37

  • Europe Heparin Market Report 2016
    Published: 02-Dec-2016        Price: US 3900 Onwards        Pages: 121
    Notes: Sales, means the sales volume of Heparin Revenue, means the sales value of Heparin This report studies sales (consumption) of Heparin in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Hepalink - Changshan Biochemical - Qianhong Bio-pharma - Opocrin - Pfizer......
  • Global Thrombin (Human) Market Research Report 2016
    Published: 29-Nov-2016        Price: US 2900 Onwards        Pages: 109
    Notes: Production, means the output of Thrombin (Human) Revenue, means the sales value of Thrombin (Human) This report studies Thrombin (Human) in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Baxter - CSL - Bayer - Grifols - Octapharma - Shan......
  • Global Heparin Sales Market Report 2016
    Published: 25-Nov-2016        Price: US 4000 Onwards        Pages: 129
    Notes: Sales, means the sales volume of Heparin Revenue, means the sales value of Heparin This report studies sales (consumption) of Heparin in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Hepalink - Changshan Biochemical - Qianhong Bio-pharma - Opocrin - Pfi......
  • Global Heparin Sodium Market Research Report 2016
    Published: 25-Nov-2016        Price: US 2900 Onwards        Pages: 109
    Heparin sodium is an anticoagulant (blood thinner) that prevents the formation of blood clots. With the accelerated pace of life and increasing aging population, global morbidity and mortality of cardiovascular and cerebrovascular disease are increased year by year. Heparin sodium is an efficient solution to those diseases. With increasing downstream demand, global heparin sodium production also increased from 133698 Kg in 2011 to 189515 Kg in 2015, with an average increase rate of 9.11%. ......
  • Osteonecrosis - Pipeline Review, H2 2016
    Published: 23-Nov-2016        Price: US 2000 Onwards        Pages: 40
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis - Pipeline Review, H2 2016, provides an overview of the Osteonecrosis (Musculoskeletal Disorders) pipeline landscape.Osteonecrosis is bone death caused by poor blood supply to the area. It is most common in the hip and shoulder, but can affect other large joints such as knee, elbow, wrist and ankle. Osteonecrosis can be caused by disease, or a severe trauma, such as a break or dislocation, that a......
  • Thrombocytopenia - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 163
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombocytopenia - Pipeline Review, H2 2016, provides an overview of the Thrombocytopenia (Hematological Disorders) pipeline landscape.Thrombocytopenia is characterized by an abnormally low amount of platelets Low platelet levels occur due to less production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream or in the spleen or liver. Symptoms include bleeding in the mouth and......
  • Global Heparin Sodium Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 08-Nov-2016        Price: US 3480 Onwards        Pages: 116
    Heparin sodium is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Scope of the Report: This report focuses on the Heparin Sodium in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, re......
  • Global Heparin Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 07-Nov-2016        Price: US 3480 Onwards        Pages: 114
    Heparin, a highly sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machineScope of the Report:This report focuses on the Heparin in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and ......
  • Vasculitis-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Vasculitis-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Vasculitis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, funding......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs